Loading viewer...
earnings
Format: PDF earnings
Karyopharm Therapeutics presented second quarter 2022 financial results and business updates on August 4, 2022, featuring commercial highlights for XPOVIO and pipeline developments for selinexor and eltanexor. The presentation includes financial guidance, drug development updates, and forward-looking statements regarding commercialization efforts in multiple myeloma and diffuse large B-cell lymphoma.
conference
34 Pages
earnings
12 Pages
Destination XL Group
UOB Group Robust Results Aug 2023 Earnings
earningsearnings
51 Pages
United Overseas Bank Limited